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Abstract
Background: Reduced vocal intensity is a core impairment of hypokinetic dysarthria in Parkinson’s disease (PD).
Speech treatments have been developed to rehabilitate the vocal subsystems underlying this impairment. Intensive
treatment programs requiring high-intensity voice and speech exercises with clinician-guided prompting and
feedback have been established as effective for improving vocal function. Less is known, however, regarding long-
term outcomes of clinical benefit in speakers with PD who receive these treatments.
Methods: A retrospective cohort design was utilized. Data from 78 patient files across a three year period were
analyzed. All patients received a structured, intensive program of voice therapy focusing on speaking intent and
loudness. The dependent variable for all analyses was vocal intensity in decibels (dBSPL). Vocal intensity during
sustained vowel production, reading, and novel conversational speech was compared at pre-treatment, post-
treatment, six month follow-up, and twelve month follow-up periods.
Results: Statistically significant increases in vocal intensity were found at post-treatment, 6 months, and 12 month
follow-up periods with intensity gains ranging from 5 to 17 dB depending on speaking condition and measurement
period. Significant treatment effects were found in all three speaking conditions. Effect sizes for all outcome measures
were large, suggesting a strong degree of practical significance.
Conclusions: Significant increases in vocal intensity measured at 6 and 12 moth follow-up periods suggested that the
sample of patients maintained treatment benefit for up to a year. These findings are supported by outcome studies
reporting treatment outcomes within a few months post-treatment, in addition to prior studies that have reported
long-term outcome results. The positive treatment outcomes experienced by the PD cohort in this study are consistent
with treatment responses subsequent to other treatment approaches which focus on high-intensity, clinician guided
motor learning for voice and speech production in PD. Theories regarding the underlying neurophysiological response
to treatment will be discussed.
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Background
Among the physiological impairments resulting from
Parkinson’s disease (PD) include the onset and progres-
sion of hypokinetic dysarthria. Hypokinetic dysarthria in
PD is characterized by deviations in the rate, range,
force, and tone of neuromuscular function in the mus-
cles underlying speech production [1]. These deviations
translate to effects on speech that include abnormalities
in articulation and phonation. The classic clinical pres-
entation of speech impairment in PD is characterized by
a perceptually salient low volume and breathy voice
quality, short rushes of speech, and imprecise articula-
tion [2]. These vocal abnormalities result from impair-
ments to neuromuscular control of respiratory and
laryngeal muscles which numerous treatments, both
medical and behavioral, have aimed to improve.
The pathophysiology of PD is linked to basal ganglia
dysfunction and/or neural networks tied to this system.
Unlike the limb effects of PD, however, evidence for
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pharmaceutical and surgical treatments improving hypo-
kinetic dysarthria has been equivocal, suggesting that
speech and voice manifestations of PD are influenced by
pathways related to, but outside, the basal ganglia nuclei
[3]. The model of PD progression proposed by Braak et
al. (2004) suggested that early stage PD is characterized
by neuronal impairment in the medulla and pons, in-
cluding nuclei of the vagus and glossopharyngeal nerves
[4]. Sapir (2014) has suggested that this model could ex-
plain why hypokinetic dysarthria is not sensitive to
dopamine replacement therapy (cranial nerves are influ-
enced by dopaminergic pathways, but do not directly
utilize dopamine for neuronal communication) [3]. The
muted effect of medication for treating the voice mani-
festations of PD, specifically the glottal incompetence
resulting in low volume which progresses along with the
disease, lends support to that position.
The laryngeal dysfunction resulting from hypokinetic
dysarthria in PD is manifested by glottal incompetence
due to bowing of the vocal folds, in some cases with ac-
companying atrophy [5]. The perceptual and physio-
logical consequences of this impairment are reduced
speech volume and vocal sound intensity, respectively.
In theory these changes result from rigidity (Hyperton-
icity) in respiratory and laryngeal muscles due to the
extrapyramidal dysfunction underlying the disease, al-
though alternative theories of hypotonicity have also
been presented [6–9]. In addition, alternative explana-
tions for hypokinetic dysarthria tying voice and speech
effects to factors other than rigidity have been proposed.
Among these include impaired scaling of vocal effort
resulting in the reduced vocal amplitude that is charac-
teristic of speakers with PD [3]. This theory links the
basal ganglia mediation of physical effort sense to the re-
duced vocal effort and subsequent low volume charac-
terizing speech patterns of speakers with PD.
Bowed vocal folds are a characteristic of some
speakers with PD, and surgical correction for the glot-
tal incompetence has primarily involved injection lar-
yngoplasty [10, 11]. Injectable substances are temporary,
however, and repeated injections would be required for
continuing improvement of glottal closure. Alternatively, a
number of voice therapy approaches have demonstrated
effective short and long-term outcomes for improving
vocal amplitude and perceptual voice quality in popula-
tions with PD. A ubiquitous characteristic of voice therapy
treatments for glottal incompetence, including those asso-
ciated with PD, is a focus on high intensity (e.g., large
number of repetitions) clinician guided exercise to pro-
mote adaptation in muscles and neurological pathways,
and increased muscular effort to increase motor unit re-
cruitment and the resulting amplitude of motor activity.
These treatments target the issue of underscaling of vocal
effort which is ubiquitous in speakers with PD [3].
A well-known evidence-based approach for treating
the respiratory and laryngeal impairments in PD is the
Lee-Silverman Voice Treatment (LSVT), now known as
LSVT LOUD®. This structured intervention targets vocal
effort scaling through increased vocal loudness via inten-
sive, high effort vocalization and speech exercises de-
signed to transfer to activities of daily living by
improving neuromotor abilities and recalibrating the pa-
tients’ perception of effort during speech production
[12]. LSVT utilizes a singular target and cueing strategy
of “think loud” with the aim of facilitating neuromotor
adaptation during speech production so that the elevated
level of effort and resulting increased amplitude of
motor activity becomes automatic and is perceived as
natural by the patient. A number of modifications to the
traditional LSVT method (16 treatment sessions over 4
consecutive weeks) have been described, including the
employment of distance technologies and reduced fre-
quency of sessions (e.g., 2× per week over 8 weeks), with
similar reported treatment outcomes [13, 14]. Interest-
ingly, the focus on increasing the amplitude of motor ac-
tivity during LSVT has also been shown to improve
articulation and swallowing abilities in some patients, re-
portedly due to carry-over effects in neuromotor abilities
associated with structures and pathways tangentially
trained in the LSVT exercises [15–17].
Vocal effort scaling and the underlying glottal incom-
petence in some speakers with PD has also been treated
with other voice therapy approaches whose clinical goals
relate to a similar focus on increased motor amplitude.
A recent report described Phonation Resistance Training
Exercise (PhoRTE) therapy applied to 60 individuals with
glottal incompetence due to presbyphonia. The therapy
tasks required of patients receiving PhoRTE were
adapted from LSVT but differed in the frequency of
treatments (1× per week instead of 4×), the incorpor-
ation of high pitch and low pitch productions of func-
tional phrases, and a less rigorous home practice
schedule. The authors reported significant improve-
ments in participants’ perceptions of quality of life and
perceived effort of voice production. These outcomes
were similar to a comparison treatment, Vocal Function
Exercises, and both experimental treatments resulted in
greater clinical improvement compared to a control
group who received no intervention [18].
Another related treatment focusing on vocal scaling,
called “SPEAK OUT!®”, targets vocal effort by prompting
patients to speak with “intent”, defined and modeled as a
purposeful cognitive focus on increasing vocal loudness
and intonation variability during speech [19]. Similar to
LSVT, this treatment requires an intensive program al-
though the number of treatment sessions is based on pa-
tient progress (e.g., 16 sessions are not required, as were
in the original method for LSVT) and sessions last
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approximately 45 min. Each treatment session is struc-
tured with a hierarchy of speech, voice, and cognitive ex-
ercises progressing in the following manner: warm-up
vocalizations → sustained vowel production → pitch
glides → counting → reading → cognitive exercises. In
the published literature, outcome data from only six pa-
tients receiving this treatment has been reported [20].
Reports which document clinical outcomes from larger
samples, both in retrospective and prospective designs,
will better inform clinical practice and evidence-based
application of treatment approaches. The purpose of the
present study was to investigate clinical outcomes in a
large case series of patients who have received the
SPEAK OUT! treatment in an effort to determine if
measures of vocal function in patients with PD are posi-
tively or negatively impacted by this approach, and to




This study used a retrospective design analyzing existing
data from a consecutive case series of patients meeting
inclusion criteria over a 3 year period. The primary out-
come variable was vocal intensity (dBSPL) measured in
three different speaking conditions: sustained vowel,
reading, and conversation. Available data from records
of patients within the cohort who were measured at
6 months and 1 year post-treatment was also collected.
The methodology for this study was approved by a uni-
versity Institutional Review Board (IRB# 1501–012–
1501). The author has no competing interests to declare.
Study population
Data for this study was collected from patient records of
the clinical population at Parkinson Voice Project in
Richardson, TX, who were treated between March 2011
and October 2014, who completed at least 12 treatment
sessions and for whom pre-treatment and post-
treatment data were recorded. All data came from pa-
tients diagnosed with idiopathic PD and who were ex-
periencing vocal impairments. Of 100 consecutive
patient files, 78 completed at least 12 treatment sessions
before post-treatment measures were collected. Of the
22 who did not complete 12 treatments, reasons in-
cluded (a) meeting treatment goals prior to 12 treat-
ments or (b) illness or other life situations requiring
withdrawal from treatment. When available, data was
also recorded from post-treatment follow-up periods at
approximately six months and twelve months.
Description of the SPEAK OUT! therapy program
Data was recorded from patient files that underwent at
least 12 treatment sessions. Each treatment was
organized around a hierarchical framework through
which a patient progressed during the course of a 45-
minute (approximate) session and during home practice
(once daily on treatment days, twice daily on non-
treatment days). Clinicians administering treatment
attended a training workshop specific to the intervention
protocol which was administered by experienced clini-
cians, and each had more than two years of clinical ex-
perience. Each patient whose file was included in this
study received three treatment sessions per week and
completed homework exercises for which they returned
homework logs at the subsequent treatment session.
Each treatment and homework session followed the
exact organizational framework, with stimuli printed in
a therapy workbook provided to the patient who placed
it open and in front of them during each session. The
treatment hierarchy was as follows:
1. Warm-up vocalizations on nasal words (e.g., “may”,
“me”, “my”)
2. Sustained vowel productions
3. Vowel pitch glides
4. Counting
5. Reading (phrases, sentences, and paragraphs)
6. Cognitive exercises (conversational speech) – these
exercises provided written prompts to the patient in
the form of carrier phrases which required the
patient to complete in sentence form and then
extend in conversation by providing the clinician
with additional novel information about the topic.
The cognitive exercises focused on improving word
retrieval and processing speed. These responses
required each patient to generate novel information
while focusing on the treatment goal of speaking
with intent.
The primary treatment goal and cueing strategy for
treatment sessions was for each patient to speak with
“intent”. Prior to the initiation of treatment, each partici-
pant was seen for a “Parkinson’s Information Session” in
which the concept of “intent” was explained to them and
treatment only began after a patient indicated under-
standing of the concept. “Intent” was defined as a pur-
poseful cognitive focus in which the patient would direct
attentional capacities on speech production. Cues such
as “speak with authority,” “use your CEO voice,” and
“say it with gusto” were associated with the concept of
“intent” and utilized during treatment sessions. Confirm-
ation of speaking intent included an increase in vocal
loudness combined with variation of intonation which
approximated more natural speech prosody during con-
nected speech utterances. Patients were asked to speak
with “intent” for every production throughout the treat-
ment hierarchy. During treatment sessions, patients
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were cued by asking them to determine if prior utter-
ances were produced with “intent” or not, and where ap-
propriate “intent” was modeled for them by the
clinician.
Measures
Data for this study was collected from daily treatment
logs of each patient, as recorded by the treating clinician.
The Parkinson Voice Project has standardized their
method of data collection during each treatment session,
as follows:
 Patients were seated in front of a desk, behind
which the clinician sat.
 A digital sound level meter (Radio Shack model 33–
2055) was placed via a stand on the desktop in front
of the patient, with the microphone head placed at
arm’s length specific to each patient (determined by
the patient extending their arm while seated
comfortably, and the clinician placing the
microphone head of the sound level meter at the
patient’s wrist). This resulted in varied mouth-to-
microphone distances between patients, but exact
mouth-to-microphone distances within patients so
that valid measures of vocal intensity could be com-
pared across sessions. The interpatient variation in
mouth-to-microphone distance was considered min-
imal, and the background noise in treatment rooms
was less than 45dBSPL. The response rate of the
sound level meter was set to fast.
 Patients were asked to produce any utterance while
facing the clinician (with mouth directed toward
microphone head of sound level meter).
 For each production within the hierarchical stages,
the clinician recorded the minimum decibel level
across the utterance duration (in dBSPL) on a daily
record sheet.
 Dependent variables for this study included dB from
three speaking conditions in the treatment
hierarchy: sustained vowels, reading and
conversation during the cognitive exercises. Mean
minimum dB averaged across the respective
utterance types at pre-treatment stages and post-
treatment stages (e.g., data collected on the 12th
treatment session, at 6-months post-treatment
follow-up and 12-months post-treatment follow-up)
were analyzed.
Statistical analysis
To compare treatment outcomes separate one-way
multivariate analyses of variance (MANOVA) with re-
peated measures were applied to the pre-treatment and
post-treatment data. Three separate MANOVA’s were
used to compare pre-treatment to initial post-treatment
measures, post-treatment at 6-months, and post-
treatment at 12-months. In these statistical models,
treatment time (pre vs. post) was the primary independ-
ent variable with decibel level in the three different
speaking contexts (vowel, reading, conversation) as add-
itional factors.
Results
The mean age of the full sample was 71.3 years, which
comprised 52 males (mean age = 72.9 years) and 26 fe-
males (mean age = 67.2 years). Mean years post-diagnosis
onset at which treatment first began was 7.0 years. Table 1
presents group descriptive statistics across the dependent
variables at the four measurement periods. Mean intensity
increased across all three dependent variables after 12
treatment sessions by approximately 17dB, 9dB, and 6 dB
for sustained vowels, reading, and conversation, respect-
ively. These increases represented large effect sizes of d =
3.56 for sustained vowel, d = 3.09 for reading, and d = 2.58
for conversation.
From among this cohort 55 patients were measured at
the 6-month follow-up period and 30 were measured
again at the 12-month follow-up. Figure 1 illustrates
mean intensity across the three speaking conditions at
pre-treatment (n = 78), post-treatment (n = 78), the first
follow-up (n = 55), and the second follow-up measure-
ment periods (n = 30). At both follow-up periods speak-
ing intensity remained above pre-treatment baseline
levels. Effect sizes for mean intensity change comparing
pre-treatment to the 6-month follow-up period
remained large at d = 3.46, d = 0.75, and d = 1.87 for
vowel, reading, and conversation, respectively. At the
12-month follow-up period effect sizes remained large at
Table 1 Descriptive statistics (mean and standard deviation in parentheses) from for the dependent variables (in dB) at the different
measurement periods
Condition Pre-Treatment Post-Treatment Follow-up 1 Follow-up 2
n = 78 n = 78 n = 55 n = 30
Sustained Vowel 71.16 (6.01) 88.34 (3.23) 88.54 (4.91) 87.43 (6.39
Reading 67.57 (3.18) 76.54 (2.58) 73.26 (10.67) 75.00 (3.70)
Conversation 66.64 (2.85) 72.89 (1.90) 71.32 (2.33) 71.33 (2.62)
Pre- and post-treatment measures reflect data from 78 patients, Follow-up 1 (at 6 months) reflect data from 55 patients, and Follow-up 2 (at 12 months) reflect
data from 30 participants
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d = 2.90, d = 2.21, and d = 1.64 for vowel, reading, and
conversation, respectively.
Three separate MANOVA’s were applied to the data to
compare pre-treatment intensity levels to those at post-
treatment, 6-month follow-up, and 12-month follow-up
periods, respectively. For the pre-treatment vs. post-
treatment analysis, there was a significant main effect for
measurement period (Pillai’s Trace = 0.793, F[3,152] =
193.7, p < 0.001) with a corresponding large effect size as
calculated by partial eta squared (η2 = 0.793), which re-
flects the error variance between the three speaking con-
ditions as a percent variance explained. In this analysis
there were significant treatment effects for sustained
vowel (F[1,154] = 494.64, p < 0.001), reading (F[1,154] =
373.12, p < 0.001), and conversation (F[1,154] = 259.72, p
< 0.001). For the pre-treatment vs. 6-month follow-up
analysis there was a significant main effect for measure-
ment period (Pillai’s Trace = 0.755, F[3,106] = 108.66, p <
0.001) with a corresponding large effect size (η2 = 0.755).
In this analysis there were significant treatment effects for
sustained vowel (F[1,108] = 329.06, p < 0.001), reading
(F[1,108] = 15.27, p < 0.001), and conversation (F[1,108] =
95.72, p < 0.001). In the pre-treatment vs. 12-month
follow-up analysis there was a significant main effect for
measurement period (Pillai’s Trace = 0.692, F[3,56] =
42.03, p < 0.001) with a corresponding large effect size (η2
= 0.685). In this analysis there were significant treatment
effects for sustained vowel (F[1,58] = 126.34,p < 0.001),
reading (F[1,58] = 73.27, p < 0.001), and conversation
(F[1,58] = 40.55, p < 0.001).
Collectively the statistical analyses revealed a significant
treatment effect on vocal intensity measured at post-
treatment, 6-month follow-up, and 12-month follow-up
when compared to pre-treatment vocal intensity. In all
comparisons vocal intensity increased as a result of treat-
ment. In addition, the results revealed that intensity in-
creased for all three speaking conditions (sustained vowel,
reading, conversation) at post-treatment, 6-month follow-
up, and 12-month follow-up, respectively, when compared
to pre-treatment measurements. For all comparisons
effect sizes were large, suggesting a strong degree of prac-
tical significance.
Discussion
The purpose of this study was to investigate clinical
outcomes in a large case series of patients who received
an intensive program of speech therapy by measuring
vocal intensity during sustained vowel, reading, and con-
versation at pre-treatment, post-treatment, and two
follow-up periods. Findings revealed a significant treat-
ment effect of on all measurements when compared to
pre-treatment levels. These treatment effects were asso-
ciated with large effect sizes. Collectively, the results of
this study further support the notion that intensive
speech and voice treatments focusing on vocal effort
scaling are effective for increasing speaking intensity sec-
ondary to Parkinson’s disease. Additionally, results from
this study suggested that treatment effects remained up
to one-year post-treatment.
The largest treatment effect in this study was found on
sustained vowel production. This was expected as both
reading and conversation required connected speech
with its variable intonation patterns resulting in a lower
mean intensity across the utterances. The influence of
speaking task on sound intensity and the differential in-
fluence of speaking task on response to treatment in pa-
tients with PD has also been demonstrated in prior
studies [21]. Although long-term treatment effects
across all speaking conditions are not unequivocal
among previously reported investigations, the significant
6-month and 12-month follow-up effects found in this
study are consistent with prior studies investigating
long-term treatment effects secondary to LSVT [21, 22].
The significant post-treatment and long-term gains in
vocal intensity subsequent to treatment are in line with
outcomes from other evidence-based approaches which
target reduced vocal intensity subsequent to glottal in-
competence in PD or ageing. Interventions such as
SPEAK OUT!, LSVT, and PhoRTE share methodological
characteristics including high-intensity exercise protocols
Fig. 1 Mean minimum intensity (in dB) levels across the three speaking condition at four measurement timeframes: pre-treatment (n = 78), post-
treatment (n = 78), Follow-up 1 @ 6-months (n = 55), and Follow-up 2 @ 12-months (n = 30)
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with clinician guided instruction and feedback to promote
sustained motor learning. Theories explaining the neuro-
physiological changes subsequent to high-intensity vocal
and speech exercises in PD have included improvement in
glottal closure and/or vocal tension for increased sound
pressure levels in speech, changes to extrapyramidal
motor functions, and changes in limbic system pathways
regulating goal-directed behavior [22]. A unique element
of the treatment employed in the current study was the
requirement for novel productions during conversational
speech as a core element of the approach. The focus on
“intent” is a method, similar to LSVT’s prompting of
“think loud”, which helps the patient to rescale vocal effort
during speech. In theory this may recruit and align cogni-
tive pathways with the direct activation pyramidal path-
ways to facilitate increases in the number of motor units
recruited in respiratory and laryngeal musculature during
speech production. This hypothesis will need to be tested
in future studies.
Study limitations
This investigation was a retrospective study, which
presents limitations on interpretation due to the na-
ture of the research design. Important among these
limitations were the inability to control for con-
founding factors that may have influenced within-
subject responses to treatment (i.e., clinician differ-
ences, medication types/levels/schedule). Related to
this, there was no comparison with a control group,
so any improvement measured in this study may be
the result of separate factors other than or in
addition to the intervention. Due to the retrospective
nature of the design treatment fidelity could not be
assessed. Additionally, data from 22 patients among
the initial cohort of 100 was not included in the
final analysis due to lack of meeting full inclusion
criteria, and subsequent intention-to-treat analysis
was not performed. The patient cohort in this study
also included males and females, although sex was
not a factor in the study design. The degree to
which sex influences outcomes will need to be ad-
dressed in subsequent experiments. This study did
not include a rigid control over mouth-to-
microphone distance, which is known to influence
measurements of acoustic intensity. Prospective stud-
ies controlling for this factor are needed to further
validate the results of this study. The outcome mea-
sures were not blinded to treatment or time point
and were conducted by the treating clinicians, which
could have led to measurement bias. The findings
from this investigation will require validation from
future prospective studies with designs controlling
for the above mentioned limitations.
Conclusion
This study investigated the effect of an intensive speech
treatment focusing on rescaling of vocal effort to treat
reduced vocal intensity due to hypokinetic dysarthria in
PD. Retrospective data from 78 patients was analyzed to
determine treatment effects after 12 therapy sessions
(post-treatment), at a 6 month follow-up period, and at
a 12 month follow-up period. Statistical analyses re-
vealed significant treatment effects in the form of in-
creased vocal intensity in sustained vowels, reading, and
conversation at all three post-treatment measurement
periods. These findings support the need for future pro-
spective studies which control for additional factors as
part of the scientific design. The positive treatment out-
comes experienced by the PD cohort in this study are
consistent with treatment responses subsequent to other
treatment approaches which focus on high-intensity,
clinician guided motor learning for voice and speech
production in PD.
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